Short-term repopulating cells with myeloid potential in human mobilized peripheral blood do not have a side population (SP) phenotype.
Clinical use of purified hematopoietic stem cells in myeloablated patients requires cotransplantation of short-term repopulating cells (STRCs) to ensure timely count recovery. Here, we investigated the flow fluorescence-based side population (SP) phenotype of mobilized human peripheral blood (mPB) cells that rapidly repopulate the highly permissive nonobese diabetic/severe combined immunodeficient (NOD/SCID)-beta2 microglobulin(-)/- mouse. No SP cells from this source regenerated detectable progeny in these mice before 8 weeks, although by 12 weeks human B-lymphoid cells were seen in some recipients of SP mPB cells. All myeloid reconstituting activity, including that seen within 3 weeks after transplantation, was associated with the non-SP fraction. Isolation of SP cells depletes human mPB of the rapid myeloid reconstitution capacity provided by myeloid-restricted STRCs which are vital for early hematologic recovery in clinical transplant recipients.
Fischer
Marlene
M
Department of Internal Medicine I, Albert-Ludwigs-University, Freiburg, Germany.
Schmidt
Manfred
M
Klingenberg
Silke
S
Eaves
Connie J
CJ
von Kalle
Christof
C
Glimm
Hanno
H
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D006085:Graft Survival; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D016513:Mice, SCID; D038042:Myelopoiesis; D036102:Peripheral Blood Stem Cell Transplantation; D010641:Phenotype; D014183:Transplantation, Heterologous; D001613:beta 2-Microglobulin / Q000172:deficiency / Q000235:genetics
D001613:beta 2-Microglobulin